https://www.marketwatch.com/story/...-03?siteid=yhoof2&yptr=yahooAnalysts there predict that remdesivir, Gilead's experimental COVID-19 treatment that has
received an emergency use authorization from the Food and Drug Administration, will generate
annual peak revenue
of $7.7 billion in 2022.
They are also in support of Gilead's recent investment in Arcus Biosciences Inc. RCUS, +4.47%, which gives the drugmaker "critical mass in oncology.".
"With these additional opportunities we believe a valuation of $94+ is realistic,
perhaps as soon as the company declares its price for commercial sale of remdesivir," SVB Leerink analyst Geoffrey Porges wrote.
He expects Gilead to price remdesivir at around $5,000 for a course of treatment,
at the list price in the U.S. Gilead's stock is up 12.7% year-to-date,
while the S&P 500 SPX, +0.82% is down 4.6%.
Thread abonnieren
